

## Special Article - Deep Vein Thrombosis

# Platelet and Microvesicles Derived in Venous Thromboembolism: Call to Be Aware

Signorelli SS\*

Department of Medical and Experimental Medicine,  
University of Catania, Italy

\*Corresponding author: Signorelli SS, Professor of Internal Medicine, Department of Clinical and Experimental Medicine, University of Catania (Italy) University Hospital "G.Rodolico" Via S.Sofia Code 95123 – Catania, Italy


Received: July 05, 2019; Accepted: July 10, 2019;

Published: July 17, 2019

## Short Communication

Venous Thromboembolism (VTE) affects a number of individuals it is frequently diagnosed in patients hospitalized for chronic diseases (i.e. cardiac, cerebral, inflammatory disease, trauma, surgical procedures) or having thrombophilia (i.e. factor V Leiden, mutation of pro thrombin G210A, deficiency of protein C and S, anti thrombin 3<sup>rd</sup> deficiency, mutation of MTHFR enzyme, hyperhomocysteinemia) [1-7]. Hypercoagulable condition plays a crucial role for VTE consequently, factors of coagulative cascade are highly considered both as pathogenetic tools, and in threatening the VTE. Diversely, there is a few interest on the role played by Platelets (P) in VTE. P is widely accepted as a pivotal mechanism involved in arterial thrombosis in fact anti platelet drugs are assigned both to prevent and to cure arterial thrombosis (Figure 1). However, there are such evidences from studies on pathophysiological role of P and on possible efficacy of anti platelet drugs in preventing the VTE or in reducing its frequency [8-12]. Acetyl salicylic acid was considered for VTE prophylaxis, achieving to the risk reduction of VTE in primary and in secondary prevention. Genetic and functional activation of P, spatial or volumetric modifications were found in specific setting of VTE patients (i.e. cancer, anti phospholipid syndrome, hematologic malignancy etc.) [13-15]. However, role of P in VTE is still debated or no cleared. About P in VTE, I believe as noteworthy to highlight on microvesicles P derived as a specific pathway of clot activation in VTE. Briefly, Microparticles (MPs) are phospholipid vesicles potentially derived from the bloodstream cells (leukocyte, platelet) and from endothelial cells. Tissue Factor (TF) and Phospholipids (Phsp) are two active players leading to procoagulant capability of MPs. In this light it is noteworthy to note that surface of P derived MPs is able to bind coagulative VIII, IX, V, and X activated factors of coagulative cascade [14].

We took attention on MPs in a group of patients affected by Deep Veins Thrombosis (DVT), and we found higher generation of MPs, of phospholipids in DVT patients than in matched group of healthy controls. On the contrary, clot time generation lowered as by demonstrated by prothrombinase induced clotting time. About MPs in VTE we summarize on mixed results. In acute VTE MPs were not found [15] whereas association between MPs with TF



**Figure 1:** Mechanisms involved in provoking thrombosis. Figure focuses both on Virchow's triade components, on platelet and on platelet derived microvesicles.

was demonstrated in unprovoked DVT [15,16-18]. Consistent data showed a putative role of MPs in patients with antiphospholipid syndrome, as a key mechanism, and to be able to lead to thrombotic consequences most frequently diagnosed in these patients [19,20]. We agree with opinion from authors that MPs cannot be used as a single lab coagulative marker to screen individuals for risk of VTE [21-23]. Rather, a network of lab markers including MPs, PiCT assay, and PLPs could be added to other known coagulative markers to achieve intriguing targets. Firstly, to elicit pro-thrombotic conditions, furthermore to focus on role played by P and its derived particle as a pathophysiological mechanism in VTE [24-27]. Now we must to call be aware on role played by MPs and by the P in provoking VTE. It is particularly relevant in patients with cancer because MPs, P are closely related to the TF generation. This last pro thrombotic condition must be considered as crucial to explain high VTE frequency.

## References

- Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med. 1997; 157:1665-1670.
- Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000; 83:657-660.
- Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerström J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5: 692-699.
- Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc. 2006; 98: 1967-1972.
- Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162: 1245-1248.

6. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007; 98: 756–764.
7. Beccattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med*. 2012; 366: 1959-1967.
8. Cohen AT, Imfeld S, Markham J, Granziera S. The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. *Thrombosis Research*. 2015; 135: 217-225.
9. Collaborative overview of randomized trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. *BMJ*. 1994; 308: 235-246.
10. Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. *J Thromb Haemost*. 2010; 8: 157-162.
11. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without thromboembolism. *Thromb Res*. 2011; 127: 473-477.
12. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. *J Am Coll Cardiol* 2005; 45: 1467-1471.
13. Campello E, Spiezia L, Radu CM, Bulato C, Gavasso S, Tormene D, et al. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. *Thromb Haemost*. 2016; 115: 81-88.
14. Pigault C, Follenius-Wund A, Schmutz M, Freyssinet JM, Brisson A. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. *J Mol Biol*. 1994; 236: 199-208.
15. Balasubramanian K, Bevers EM, Willems GM, Schroit AJ. Binding of Annexin V to Membrane Products of Lipid Peroxidation. *Biochemistry*. 2001; 40: 8672-8676.
16. Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. *Thromb Res*. 2012; 129: S6-9.
17. Piccin A, Murphy WG, Smith OP. Circulating microparticle: pathophysiology and clinical implications. *Blood Rev*. 2007; 21: 157-171.
18. Thaler J, Ay C, Weinstabl H, Dunkler D, Simanek R, Vormittag R, et al. Circulating procoagulant microparticles in cancer patients. *Ann Hematol*. 2011; 90: 447-453.
19. Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W. The PICT test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study. *J Thromb Haemost*. 2016; 14: 2187-2193.
20. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. *Blood*. 2013; 122: 2011-2018.
21. Owens AP. Microparticles in hemostasis and thrombosis. *Circ Res*. 2011; 108: 1284-1297.
22. Rautou PE, Mackman N. Microvesicles as risk markers for venous thrombosis. *Expert Rev Hematol*. 2013; 6: 91-101.
23. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. *Thromb Res*. 2011; 127: 473-477.
24. Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, et al. High concentration of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. *Clin Chem*. 2007; 53: 1235-1243.
25. Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? *Br J Haematol*. 2000; 108: 191-193.
26. Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. *Thrombosis Research*. 2014; 134: 1093-1096.
27. Ferrante M, Fiore M, Conti GO, Fiore V, Grasso A, Copat C, et al. Transition and heavy metals compared to oxidative parameter balance in patients with deep vein thrombosis: A case-control study. *Molecular Medicine Reports*. 2017; 15: 3438-3444.